汇宇制药(688553.SH)：注射用紫杉醇(白蛋白结合型)获得境外上市许可

Core Viewpoint - Seacross Pharma (Europe) Ltd., a subsidiary of the company, has received marketing approvals for its injectable paclitaxel (albumin-bound) from regulatory authorities in the Netherlands, Ireland, Finland, and Sweden [1] Group 1: Product Approval - The injectable paclitaxel (albumin-bound) is indicated as a monotherapy for adult patients with metastatic breast cancer who have not responded to first-line treatment and for whom standard anthracycline-based therapy is not suitable [1] - The product is also indicated for use in combination with gemcitabine for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma [1] - Additionally, it is indicated for use in combination with carboplatin for the initial treatment of adult patients with non-small cell lung cancer who are not suitable for potentially curative surgery and/or radiotherapy [1]